20240051987. NEUROACTIVE STEROIDS SUBSTITUTED IN POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS simplified abstract (Sage Therapeutics, Inc.)

NEUROACTIVE STEROIDS SUBSTITUTED IN POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS

Organization Name

Sage Therapeutics, Inc.

Inventor(s)

Maria Jesus Blanco-pillado of Arlington MA (US)

Francesco G. Salituro of Marlborough MA (US)

Marshall Lee Morningstar of Framingham MA (US)

NEUROACTIVE STEROIDS SUBSTITUTED IN POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240051987 titled 'NEUROACTIVE STEROIDS SUBSTITUTED IN POSITION 10 WITH A CYCLIC GROUP FOR USE IN THE TREATMENT OF CNS DISORDERS

Simplified Explanation

The abstract of the patent application describes a compound and its pharmaceutically acceptable salt, along with pharmaceutical compositions containing the compound. The compound is useful in the treatment of CNS-related disorders.

• The patent application describes a compound and its pharmaceutically acceptable salt.
• The compound is represented by formula (i).
• The patent application also includes pharmaceutical compositions comprising the compound.
• The compound and compositions are useful in the treatment of CNS-related disorders.
• The patent application provides methods of using the compound for the treatment of CNS-related disorders.

Potential Applications

The technology described in the patent application has potential applications in the field of medicine and pharmaceuticals. It can be used for the treatment of CNS-related disorders, which may include neurological and psychiatric conditions.

Problems Solved

The technology addresses the problem of finding effective treatments for CNS-related disorders. These disorders can have a significant impact on the quality of life of individuals, and there is a need for new and improved therapeutic options.

Benefits

The technology offers several benefits:

• The compound and its pharmaceutically acceptable salt provide a new treatment option for CNS-related disorders.
• The pharmaceutical compositions offer a convenient and effective way to administer the compound.
• The methods described in the patent application provide guidance on the use of the compound for the treatment of CNS-related disorders.

Original Abstract Submitted

or a pharmaceutically acceptable salt thereof, wherein n, r, r, r, r, r, r, r, r, r, r, r, r, r, r, r, r, r, r, r, rand rare defined herein. also provided herein are pharmaceutical compositions comprising a compound of formula (i) and methods of using the compounds, e.g., in the treatment of cns-related disorders.